(2S)-2-(羟基氨基)-6-氧代己酸 | 30382-02-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (2S)-2-(羟基氨基)-6-氧代己酸
• 英文名称: Norleucine, 5-hydroxy-6-oxo-
• 英文别名: (2S)-2-(hydroxyamino)-6-oxohexanoic acid
• CAS: 30382-02-6
• 化学式: C₆H₁₁NO₄
• 分子量: 161.16
• InChiKey: CXAAXGOVDUQITP-YFKPBYRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.2
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  86.6
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Modification of collagenous materials and medical treatment, diagnosis and monitoring of fibrotic conditions
  申请人：Nederlandse Organisatie voor Toegepast-Natuurwetenschappelijk Onderzoek TNO

  公开号：EP1375510A1

  公开（公告）日：2004-01-02

  The present invention relates to the gene PLOD2 which codes for telopeptide lysyl hydroxylase (TLH). This enzyme converts telopeptidyl Lys into telopeptidyl Hyl, that can subsequently be converted into hydroxyallysine cross-links. Collagen with hydroxyallysine cross-links shows a higher resistance to degradation by proteinases than collagen with cross-links derived from allysine. In one aspect, the invention provides methods and compositions to prepare collagenous materials with varying biodegradation rates by varying the ratio of hydroxyallysine cross-links over allysine cross-links. In another aspect, the invention provides methods and compositions to lower the ratio of hydroxyallysine cross-links over allysine cross-links in fibrotic processes, in order to obtain a collagenous network that is more easy to degrade. Furthermore, the invention provides methods to diagnose and/or monitor fibrotic processes by measuring mRNA levels of PLOD2, by measuring protein levels of the translated mRNA, and/or by measuring enzymatic activity levels of TLH. The invention also provides the description of a high through-put system facilitating the screening of antagonists of telopeptide lysyl hydroxylase.

  本发明涉及编码端肽赖氨酰羟化酶（TLH）的基因 PLOD2。这种酶可将端肽赖氨酸转化为端肽羟基，然后再转化为羟基烯丙基氨酸交联。与具有烯丙基氨酸交联的胶原蛋白相比，具有羟基烯丙基氨酸交联的胶原蛋白具有更强的抗蛋白酶降解能力。 一方面，本发明提供了通过改变羟基烯丙基氨酸交联与烯丙基氨酸交联的比例来制备具有不同生物降解率的胶原蛋白材料的方法和组合物。另一方面，本发明提供了在纤维化过程中降低羟基烯丙基氨酸交联与烯丙基氨酸交联比例的方法和组合物，以获得更易于降解的胶原蛋白网络。此外，本发明还提供了通过测量 PLOD2 的 mRNA 水平、测量翻译后 mRNA 的蛋白质水平和/或测量 TLH 的酶活性水平来诊断和/或监测纤维化过程的方法。本发明还描述了一种高通量系统，便于筛选端肽赖氨酰羟化酶的拮抗剂。
• Compositions for repairing and regenerating human dura mater
  申请人：BAXTER INTERNATIONAL INC.

  公开号：EP1484070A1

  公开（公告）日：2004-12-08

  A method of using a substantially non-porous equine collagen foil to repair and regenerate dura mater tissue of mammals when the dura mater tissue is damaged as a result of injury, tumors, surgery, and the like. The non-porous equine collagen foil comprises collagen fibrils which provides a replacement dura mater composition that is elastic, liquid-tight, and which has a high tensile strength. The non-porous equine collagen foil is furthermore resorbable and provides a biomatrix, wherein a neodura is rapidly formed which becomes indistinguishable from the autologous dura mater in a matter of weeks. The process for making the equine collagen foil reduces the likelihood of disease transmission.

  当哺乳动物的硬脑膜组织因损伤、肿瘤、手术等原因受损时，使用一种基本无孔的马胶原蛋白箔修复和再生硬脑膜组织的方法。无孔马胶原蛋白箔由胶原纤维组成，可提供具有弹性、液密性和高拉伸强度的替代硬脑膜组合物。此外，无孔马胶原蛋白箔还具有可吸收性，提供了一种生物基质，可迅速形成新硬脑膜，并在数周内变得与自体硬脑膜无异。马胶原蛋白箔的制作过程降低了疾病传播的可能性。
• Method for preparing a modified protein outside a host cell
  申请人：Nederlandse Organisatie voor Toegepast-Natuurwetenschappelijk Onderzoek TNO

  公开号：EP1584630A1

  公开（公告）日：2005-10-12

  The present invention relates to a method for preparing a modified folded protein, comprising modifying unfolded α-chains comprising a collagenous amino acid sequence and thereafter folding at least part of the modified α-chains into a quaternary protein structure, in particular a helical protein structure. The invention allows for an attractive alternative for making recombinant proteins, such as recombinant collagens and the like, which may be used in a variety of biomedical and other applications.

  本发明涉及一种制备修饰折叠蛋白的方法，包括修饰包含胶原氨基酸序列的未折叠 α-链，然后将至少部分修饰的 α-链折叠成四级蛋白结构，特别是螺旋蛋白结构。本发明为制造重组蛋白质（如重组胶原蛋白等）提供了一种有吸引力的替代方法，可用于各种生物医学和其他应用领域。
• Use of corneal hardening agents in enzymeorthokeratology
  申请人：——

  公开号：US20030175259A1

  公开（公告）日：2003-09-18

  An Enzyme Orthokeratology method is provided for correcting refractive errors in the eye of a subject mammal. Accelerating reshaping of the cornea is accomplished by administering a corneal hardening amount of a corneal hardening agent to the eye of the subject. Reformation is accomplished under the influence of a rigid contact lens or a series of lenses having a concave curvature that will correct a refractive error. The cornea rapidly reshapes its convex curvature to the concave curvature of the contact lens, rendering the eye emmetropic. The cornea is permitted to “harden” to retain the new emmetropic shape. After “hardening” has occurred, the lens rendering the eye emmetropic is removed.

  提供了一种用于矫正哺乳动物眼睛屈光不正的酶角膜塑形法。通过向受试者的眼睛注射一定量的角膜硬化剂，加速角膜的重塑。在硬性隐形眼镜或一系列具有凹面弧度的镜片的影响下，完成角膜重塑，从而矫正屈光不正。角膜会迅速按照隐形眼镜的凹面弧度重塑其凸面弧度，从而使眼睛呈现屈光不正。角膜被允许 "硬化"，以保持新的屈光形状。在 "硬化 "完成后，摘除使眼睛变偏光的镜片。
• Method for detecting rheumatoid arthritis employing the CB10 peptide of mammalian type II collagen as an antigen
  申请人：MONTECH MEDICAL DEVELOPMENTS PTY. LTD.

  公开号：US20040157265A1

  公开（公告）日：2004-08-12

  An highly specific and sensitive approach to detecting antibodies to collagen in a biological sample entails contacting the sample with an antigen that comprises the CB10 peptide of mammalian type II collagen, or with an antibody-binding fragment of that peptide, under conditions conducive to formation of an antibody-antigen complex, which then is detected.

  检测生物样本中胶原蛋白抗体的特异性和灵敏度极高的方法是将样本与抗原接触，抗原包括哺乳动物 II 型胶原蛋白的 CB10 肽或该肽的抗体结合片段，在有利于形成抗体-抗原复合物的条件下，检测抗体-抗原复合物。